drugset / Trial / NCT00312013
Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer or non-small-cell lung carcinoma (NSCLC).
Timeline
- Start
- 2006-05
- Primary completion
- 2009-07
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nadroparin Calcium | Other / unclassified | — | Subcutaneous |